ストックスクリーナーアプリを入手
32.70
3.78%
1.19
アフターアワーズ：
32.70
前日終値:
$31.51
開ける：
$32.28
24時間の取引高:
1.26M
Relative Volume:
0.54
時価総額：
$3.99B
収益：
$1.24B
当期純損益:
$209.00M
株価収益率:
19.69
EPS:
1.6605
ネットキャッシュフロー:
$-94.86M
1週間 パフォーマンス:
+7.07%
1か月 パフォーマンス:
+4.37%
6か月 パフォーマンス:
+33.58%
1年 パフォーマンス:
+262.93%
1日の値動き範囲:
$31.74
$32.83
1週間の範囲:
$30.11
$33.62
52週間の値動き範囲:
$8.69
$38.00
Indivior Pharmaceuticals Inc Stock (INDV) Company Profile
名前
Indivior Pharmaceuticals Inc
セクター
電話
804-379-1090
住所
10710 MIDLOTHIAN TURNPIKE, NORTH CHESTERFIELD
Compare INDV vs TAK, ZTS, HLN, TEVA, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
INDV
Indivior Pharmaceuticals Inc
|
32.70 | 3.99B | 1.24B | 209.00M | -94.86M | 1.6605 |
TAK
Takeda Pharmaceutical Co Adr
|
17.82 | 56.30B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
122.38 | 51.46B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.75 | 43.42B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.40 | 37.73B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
588.38 | 25.79B | 3.18B | 1.33B | 1.04B | 27.90 |
Indivior Pharmaceuticals Inc Stock (INDV) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-08-06 | 開始されました | H.C. Wainwright | Buy |
| 2025-07-22 | 再開されました | Jefferies | Buy |
| 2025-01-28 | 開始されました | Rodman & Renshaw | Buy |
| 2024-07-23 | 開始されました | Piper Sandler | Overweight |
| 2024-04-03 | 開始されました | Craig Hallum | Buy |
| 2023-07-13 | 開始されました | Northland Capital | Outperform |
すべてを表示
Indivior Pharmaceuticals Inc (INDV) 最新ニュース
Indivior Pharmaceuticals Inc. (INDV) Tops Q4 Earnings and Revenue Estimates - Eastern Progress
Indivior Pharmaceuticals Inc (INDV) Shares Fall 3.1% -- What GF Score of 69 Tells Investors - GuruFocus
Indivior Pharmaceuticals (INDV) Valuation Check After Recent Share Price Volatility - Yahoo Finance
Indivior PLC Survey Highlights Correctional Leaders' Support for Long-Acting Injectable Buprenorphine to Mitigate MOUD Diversion - Quiver Quantitative
Survey of Correctional Facility Staff: Monthly Opioid Treatment Shot May Help Reduce Medication Misuse - ChartMill
INDV Insider Filing: Barry Patrick Restricted Stock Units April 2026 - Meyka
KYMR Stock Up as FDA Grants Fast Track Designation to Asthma Drug - The Globe and Mail
Assessing Indivior (INDV) Valuation After New SUBLOCADE Study In Correctional Healthcare - Sahm
Cipher Mining Stock, Five Below, Indivior Among 10 New Stocks On IBD Watchlists - Investor's Business Daily
A Look at Indivior Pharmaceuticals Inc (INDV) After 3.5% Gain -- GF Value $21.93 vs Price $31.60 - GuruFocus
Has The Strong Three-Year Run Left Indivior Pharmaceuticals (INDV) Priced Too Richly Today? - Yahoo Finance
How much upside is left in Indivior Pharmaceuticals Inc. (INDV)? Wall Street analysts think 45.99% - MSN
Indivior, Liquidia, Crinetics top Quant pharma list as Merck scoops up Terns for $6.7B - MSN
Indivior Lends Voice to Help Raise Awareness of Substance Use Di - GuruFocus
If You Invested $1,000 in Indivior Pharmaceuticals Inc. (INDV) - Stock Titan
Indivior Pharmaceuticals Inc (INDV) Stock Down 5.5% but Still Overvalued -- GF Score: 72/100 - GuruFocus
Indivior Pharmaceuticals Inc (INDV) Stock Down 5.5% but Still Ov - GuruFocus
IBRX Stock Rises 7% on Strong Q1 2026 Preliminary Results - TradingView — Track All Markets
Down 12.9% in 4 Weeks, Here's Why You Should You Buy the Dip in Indivior Pharmaceuticals Inc. (INDV) - MSN
KYMR Set to Earn Milestone Payment as GILD Secures License for KT-200 - TradingView
How Much Upside is Left in Indivior Pharmaceuticals Inc. (INDV)? Wall Street Analysts Think 45.99% - Yahoo Finance
Could Indivior (INDV) Turn Correctional Staffing Efficiencies Into a Durable Competitive Edge? - Sahm
Indivior to Report Q1 2026 Earnings, Host Webcast - National Today
Indivior to Report First Quarter 2026 Financial Results - National Today
Indivior to Report First Quarter 2026 Financial Results and Host Webcast on April 30th - The Manila Times
Zacks Industry Outlook Features Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics, and Avalo Therapeutics - Bitget
IMVT Stock Falls 2.4% as Batoclimab Misses Late-Stage Study Endpoints - TradingView — Track All Markets
Zacks Industry Outlook Highlights Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics and Avalo Therapeutics - zacks.com
INDV Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
INDV | Indivior Pharmaceuticals, Inc. Common Executive Compensation - Quiver Quantitative
INDV Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
INDV Technical Analysis & Stock Price Forecast - Intellectia AI
Assessing Indivior Pharmaceuticals (NasdaqGS:INDV) Valuation After New SUBLOCADE Cost Savings Evidence In Corrections Settings - Sahm
Indivior Pharmaceuticals Inc. R (E7P.F) Insider Ownership & Holdings - Yahoo! Finance Canada
JPMorgan Chase & Co. Has $5.01 Million Holdings in Indivior PLC $INDV - MarketBeat
Did Potential Jail Staffing Efficiencies From SUBLOCADE® Just Shift Indivior Pharmaceuticals' (INDV) Investment Narrative? - Sahm
Indivior Pharmaceuticals, Inc. (INDV) stock price, news, quote and history - Yahoo Finance UK
Small Cap Index Trust's Indivior Pharmaceuticals Inc(INDV) Holding History - GuruFocus
Indivior Pharmaceuticals Inc. R (E7P.F) Analyst Ratings, Estimates & Forecasts - Yahoo! Finance Canada
Indivior Pharmaceuticals, Inc. (INDV) Stock forecasts - Yahoo Finance UK
INDV Stock Price, Quote & Chart | INDIVIOR PHARMACEUTICALS INC (NASDAQ:INDV) - ChartMill
What Indivior Pharmaceuticals (INDV)'s Prison Cost Model Findings Mean For Shareholders - Yahoo Finance
Indivior Pharmaceuticals, Inc. (INDV) Stock Forecasts - finance.yahoo.com
Suboxone Tooth Decay Lawsuit Settlement April 2026 Update - Lawsuit Information Center
Indivior Pharmaceuticals, Inc. (INDV) Options Chain - Yahoo! Finance Canada
AGIO Rises on Mitapivat Progress Toward Accelerated Approval in SCD - theglobeandmail.com
Levi & Korsinsky Reminds Indivior Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 1, 2024INDV - marketscreener.com
Indivior Pharmaceuticals, Inc - Reuters
Ultragenyx Pharmaceutical Announces FDA Acceptance of UX016 IND - TradingView — Track All Markets
New Cost Impact Model Highlights Potential Benefits of Monthly Injectable Buprenorphine - National Today
New Cost Model Shows Monthly Injectable Buprenorphine Can Reduce Staffing Burdens in Prisons - National Today
Indivior Pharmaceuticals Inc (INDV) 財務データ
収益
当期純利益
現金流量
EPS
1.84%
6.22%
大文字化:
|
ボリューム (24 時間):